Bicara Therapeutics Inc. (BCAX) AI Stock Analysis

• Market Cap: $802.23M
• Dividend Yield: N/A
• Average Volume (3M): 524.47K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.23
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 55
• Sector: Healthcare
• Sector Strength: 74
• Industry: Biotechnology
• EPS (TTM): N/A
• Shares Outstanding: 54,536,217
• 10 Day Avg. Volume: 572,395
• 30 Day Avg. Volume: 524,466
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 0.00
• Price to Cash Flow (P/CF): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: 0.57
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $33.40
• Price Target Upside: 132.43% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 6

Bicara Therapeutics' stock score reflects its high-risk profile typical of early-stage biotechnology companies. The primary concern is the lack of revenue and dependence on external funding, but a strong cash position provides some financial stability. The technical analysis shows positive momentum, though investors should be cautious of potential overbought conditions. Traditional valuation metrics are not applicable, emphasizing the importance of monitoring R&D progress and market sentiment.

Positive Factors

Clinical Efficacy

The combination of ficerafusp alfa and Keytruda showed a higher overall response rate and complete response rate in a specific patient group compared to previous treatments.

Financial Resources

Bicara's current financial resources are expected to be sufficient to fund operations significantly beyond major upcoming data catalysts.

Market Potential

Bicara Therapeutics sees significant commercial opportunity in the HPV-negative 1L R/M HNSCC market.

Negative Factors

Efficacy Data

Updated efficacy data for ficerafusp in cSCC was a bit mixed, with ORR at 30% compared to previously 42%.

Financial Performance

Bicara reported a net loss of $0.39 per share for 4Q24, which was wider than the previously estimated net loss due to greater-than-expected operating expenses.

Regulatory Risks

Risks include negative clinical results with ficerafusp alfa, delays in advancing into registrational trials, and the inability to obtain regulatory approvals in a timely manner.

Bicara Therapeutics Inc. Business Overview & Revenue Model

Company Description

Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts. Bicara Therapeutics Inc. is a subsidiary of Biocon Limited.

How the Company Makes Money

Bicara Therapeutics Inc. generates revenue primarily through the development and commercialization of its therapeutic products. The company may earn money through licensing agreements, partnerships with larger pharmaceutical companies, and potential sales of its drug candidates once they receive regulatory approval. Additionally, Bicara might engage in collaborations for research and development to fund its projects. These partnerships can provide upfront payments, milestone payments, and royalties on future sales, thereby contributing to the company's earnings.

Bicara Therapeutics Inc. Financial Statement Overview

Summary

Bicara Therapeutics is in a high-risk phase typical for early-stage biotechnology firms, with no revenue and significant reliance on external funding. The strong cash position offers some financial flexibility, but ongoing losses and negative cash flow from operations highlight significant financial challenges. Investors should be cautious and aware of the potential for volatility as the company focuses on R&D activities.

Income Statement

Bicara Therapeutics Inc. has reported no revenue in the past three years, leading to negative EBIT and net income. The company is heavily reliant on external funding, as evidenced by its substantial negative net income and EBIT. The lack of revenue growth is a significant concern and reflects the high-risk nature of biotechnology companies in the research and development phase.

Balance Sheet

The company has a robust cash position with significant cash and short-term investments relative to its total debt, resulting in a negative net debt. However, the equity position has improved from a negative standpoint to a positive one, indicating a better capital structure. There is minimal debt, which mitigates financial risk, but the company still shows signs of instability due to fluctuating equity values.

Cash Flow

Bicara Therapeutics has negative operating and free cash flow, highlighting its reliance on financing activities to fund operations. The lack of revenue generation and continuous negative cash flow from operations is a concern. However, successful financing rounds have bolstered cash reserves, reflecting investor confidence despite operational challenges.

Breakdown
Dec 2024	Dec 2023	Dec 2022
Income Statement		Total Revenue
0.00	0.00	0.00
	Gross Profit
0.00	0.00	0.00
	EBIT
-82.39M	-39.89M	-37.66M
	EBITDA
-82.39M	-51.96M	-37.72M
	Net Income Common Stockholders
-68.00M	-51.98M	-37.84M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
489.71M	230.44M	4.16M
	Total Assets
510.00M	233.98M	6.70M
	Total Debt
738.00K	657.00K	0.00
	Net Debt
-488.97M	-229.78M	-4.16M
	Total Liabilities
18.12M	382.75M	105.51M
	Stockholders Equity
491.88M	-148.77M	-98.80M
Cash Flow		Free Cash Flow
-74.82M	-46.21M	-32.27M
	Operating Cash Flow
-74.75M	-45.63M	-32.08M
	Investing Cash Flow
-9.00K	-586.00K	-192.00K
	Financing Cash Flow
334.03M	272.50M	31.70M

Bicara Therapeutics Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
AVXL	62 Neutral	$753.67M	―	-37.72%	―	―	-3.08%
Sector *	52 Neutral	$5.28B	3.75	-42.72%	2.86%	17.70%	2.03%
DNTH	48 Neutral	$697.13M	―	-32.60%	―	351.48%	80.10%
BCAX	48 Neutral	$802.23M	―	34.94%	―	―	―
LENZ	46 Neutral	$795.49M	―	-25.68%	―	―	68.93%
ABUS	41 Neutral	$679.75M	―	-68.76%	―	-65.98%	14.00%
COGT	37 Underperform	$593.19M	―	-99.54%	―	―	-2.53%